199
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
CURRENT TRENDS IN THE DEVELOPMENT OF THE PHARMACEUTICAL
INDUSTRY: GLOBAL AND NATIONAL EXPERIENCE
Toshmamatova
А
.
А
.
1
Azlyarova G.U.
2
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
e-mail: aidatoshmamatova@gmail.com
https://doi.org/10.5281/zenodo.17332747
Relevance:
the pharmaceutical market remains one of the key sectors of the global economy:
rising healthcare expenditures, demographic changes, and technological innovations are shaping new
requirements for quality, marketing, and production localization. In 2024–2025, the United States,
China, and Germany became leaders in terms of sales volume, setting benchmarks for regulatory
frameworks and competitive practices for developing markets, including Uzbekistan.
Purpose of the study:
to analyze current global and national trends in the development of the
pharmaceutical industry in order to identify key growth drivers, barriers, and best practices, as well
as to develop practical recommendations for accelerating the harmonization of the regulatory
framework, improving production quality, and increasing the competitiveness of domestic
pharmaceutical manufacturers in regional and global markets.
Materials and methods:
Materials: open sources (national regulatory authorities and
specialized publications), legal and analytical reviews on Uzbekistan, reports from regulators in the
USA/China/Germany, and industry analytical briefs. Methods: comparative analysis of regulatory
frameworks and GMP practices, content analysis of marketing strategies and available statistical data,
synthesis of international best practices, and assessment of their applicability to the national context.
Results:
a comparative analysis was conducted of current trends in quality, marketing, and
production conditions in the pharmaceutical sector between the USA/China/Germany and the
Republic of Uzbekistan. The study identified the strengths and weaknesses of the national industry
and proposed strategic directions for its development.
Quality
Uzbekistan:
USA/Germany/China:
Active regulatory modernization,
establishment of a Certification and Inspection
Center, implementation of a national GxP
system, development of roadmaps for
harmonization with international standards.
Practice of state GMP inspections during the
registration of imported medicines.
Strict quality regulation system, regular
inspections and public reports on production
quality; strong supply chain control and risk
monitoring, active GMP updates in 2024–
2025.
Marketing
Uzbekistan:
USA/Germany/China:
Marketing practices; digital channels and
pharmaceutical marketing.
Advanced multichannel strategies, strong
digital marketing presence, targeted
engagement of physicians and patients,
significant role of pharmacovigilance and
pricing policy.
Production conditions
200
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
Uzbekistan:
USA/Germany/China:
State programs for production localization,
mandatory GMP inspections for registration,
roadmaps for standard harmonization;
infrastructure and production scale remain
limited compared to global leaders.
High degree of automation, well-developed
infrastructure for research and production,
sustainable supply chains, and significant
investment in biotechnology.
Conclusions:
the pharmaceutical industry of Uzbekistan is undergoing active transformation
and demonstrates a systematic approach to development: a regulatory framework has been
established, a national pharmacopoeia has been developed, innovation clusters are being formed, and
measures to support domestic manufacturers and investors are being implemented. At the same time,
in order to reach the level of the world’s leading pharmaceutical powers, the country needs to
accelerate the implementation of international quality standards, strengthen inspection and laboratory
infrastructure, digitalize marketing, train qualified specialists, and attract strategic investments. With
consistent implementation of these steps, Uzbekistan has the potential to secure a stable and
competitive position in both regional and international pharmaceutical markets.
